DORCHESTER WEALTH MANAGEMENT Co grew its stake in Bristol-Myers Squibb (NYSE:BMY) by 3.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,993 shares of the biopharmaceutical company’s stock after purchasing an additional 797 shares during the period. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Bristol-Myers Squibb were worth $1,325,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of BMY. Retirement Group LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $27,000. Orion Capital Management LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Perennial Advisors LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $29,000. Founders Capital Management bought a new stake in Bristol-Myers Squibb during the fourth quarter worth about $31,000. Finally, Alpha DNA Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $33,000. 72.41% of the stock is owned by institutional investors and hedge funds.
NYSE BMY traded down $0.21 during trading on Thursday, hitting $66.11. The stock had a trading volume of 293,942 shares, compared to its average volume of 12,392,085. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.58 and a current ratio of 1.67. Bristol-Myers Squibb has a 12 month low of $54.07 and a 12 month high of $67.16. The company has a market capitalization of $147.68 billion, a PE ratio of -602.85, a P/E/G ratio of 1.00 and a beta of 0.67. The company’s 50-day moving average price is $62.55 and its two-hundred day moving average price is $64.23.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.42 by $0.04. The firm had revenue of $11.07 billion for the quarter, compared to analysts’ expectations of $10.74 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The company’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.22 EPS. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 6.35 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 3rd. Stockholders of record on Thursday, April 1st will be issued a $0.49 dividend. This represents a $1.96 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend is Wednesday, March 31st. Bristol-Myers Squibb’s payout ratio is presently 41.79%.
In other news, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $62.20, for a total value of $1,555,000.00. Following the completion of the transaction, the chief executive officer now owns 528,980 shares of the company’s stock, valued at approximately $32,902,556. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.14% of the stock is currently owned by insiders.
A number of equities research analysts recently weighed in on the company. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c” rating in a report on Monday, March 8th. Truist Securities upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the stock from $66.00 to $74.00 in a research report on Monday. Truist Financial raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Truist raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Finally, Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research note on Tuesday, April 6th. Two investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $74.06.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
Featured Article: How to read a candlestick chart
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).